These trials completed more than 12 months ago and should have reported results.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
|Status||Trial ID||Title||Completion date||Category|
|Reported results||2009-012206-39||A phase II randomized, open label clinical trial in high risk percutaneous coronary intervention (PCI) patients receiving standard antithrombotic treatment plus either ALX-0081 or GPIIb/IIIa inhibitor...||2012-03-29||due-trials|
|Reported results||2010-019375-30||A Phase II, single-blind, randomised, placebo-controlled trial to study the efficacy and safety of anti-von Willebrand factor Nanobody administered as adjunctive treatment to patients with acquired th...||2014-03-14||due-trials|
|Exempt, with results||2010-022865-81||A phase I/II, multi-center, randomized, double-blind, placebo controlled study, with a single ascending dose part followed by a multiple ascending dose part, evaluating the safety, pharmacokinetics, p...||2012-10-02||not-yet-due|
|Reported results||2014-002841-23||A Phase I/IIa Multicentre Study in Otherwise Healthy Infants and Toddlers Hospitalised For and Diagnosed With Respiratory Syncytial Virus Lower Respiratory Tract Infection, Consisting of an Open-label...||2016-03-02||due-trials|
|Reported results||2014-003012-36||A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects with Moderate to Severe Rheumatoid Arthritis who are Intolerant to Methotrex...||2016-08-08||due-trials|
|Reported results||2014-003033-26||A Phase IIb Multicenter, Randomized, Double-blind, Placebo-Controlled Dose-Range Finding Study of ALX-0061 Administered Subcutaneously in Combination with Methotrexate, in Subjects with Moderate to Se...||2016-08-08||due-trials|
|Reported results||2014-003034-42||A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis who Have Completed One ...||2018-08-14||due-trials|
|Reported results||2015-000372-95||A Phase II Multicenter, Randomized, Double-blind, Placebo controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX 0061 Administered Subcutaneously in Subjects with Moderate to ...||2018-02-15||due-trials|
|Trial is partly outside EEC, and reported results||2015-001098-42||A Phase III double-blind, randomized, parallel group, multicenter placebo-controlled trial to study the efficacy and safety of caplacizumab in patients with acquired thrombotic thrombocytopenic purpur...||2017-08-16||bad-data|
|Listed as ongoing, but also has a completion date||2016-001503-23||Prospective Follow-up Study for Patients who Completed Study ALX0681-C301 (HERCULES) to Evaluate Long-term Safety and Efficacy of Caplacizumab (Post-HERCULES)||2017-05-17||bad-data|
|Trial is partly outside EEC, and reported results||2016-001651-49||A randomized, double-blind, placebo-controlled, multicenter dose ranging study of ALX-0171 in infants and young children hospitalized for respiratory syncytial virus lower respiratory tract infection||2018-05-25||bad-data|
|Completed, report not yet due||2017-003356-23||A randomized, double-blind, multicenter study to evaluate the efficacy and safety of ALX-0171 versus placebo, in addition to standard of care, in adults who have undergone hematopoietic stem cell tran...||2019-01-28||not-yet-due|